Skip to main content

Table 4 Number and proportion of patients that reached and not reached G2 at week 5

From: A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients

Visit

Statistics

BC

HNC

SOC

Xonrid® + SOC

SOC

Xonrid® + SOC

WEEK 5

NO G2

5 (27.8%)

10 (55.6%)

11 (68.8%)

13 (65.0%)

G2+

13 (72.2%)

8 (44.4%)

5 (31.3%)

7 (35.0%)

p-value (Chi-square)

 

0.09

 

0.8

Logistic regression

Odds ratio

 

0.31

 

1.18

95% CI

 

0.08–1.23

 

0.29–4.81

p-value

 

0.1

 

0.8